Stay updated with breaking news from Clinical Development Plans. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announces today that Bassem Elmankabadi, M.D. joins Foresee as a Senior Vice...
Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally...
Initial data from the Phase 1 dose escalation part of the OBT076 trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its ... iTeos Therapeutics Inc.April 10, 2021 GMT Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed EOS-448 showed preliminary signs of clinical activity as a monotherapy, including a partial response in one pembrolizumab-resistant melanoma patient, and stable ...